1056016-75-1Relevant academic research and scientific papers
Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, as new anti-malarial agents
Houz, Sandrine,Hoang, Nha-Thu,Lozach, Olivier,Le Bras, Jacques,Meijer, Laurent,Galons, Herv,Demange, Luc
, p. 15237 - 15257 (2015/01/09)
In Africa, malaria kills one child each minute. It is also responsible for about one million deaths worldwide each year. Plasmodium falciparum, is the protozoan responsible for the most lethal form of the disease, with resistance developing against the av
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1
Oumata, Nassima,Bettayeb, Karima,Ferandin, Yoan,Demange, Luc,Lopez-Giral, Angela,Goddard, Marie-Lorène,Myrianthopoulos, Vassilios,Mikros, Emmanuel,Flajolet, Marc,Greengard, Paul,Meijer, Laurent,Galons, Hervé
experimental part, p. 5229 - 5242 (2009/07/01)
Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC50: 220 nM), CDK5/p25 (IC50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1δ provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-β in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.
